TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
|Articles|April 1, 1999
The American Journal of Managed Care
- April 1999
- Volume 5
- Issue 4
Discontinuation Rates of Cholesterol-Lowering Medications
Advertisement
Articles in this issue
over 27 years ago
Medicaid Recipients' Experiences Under Mandatory Managed Careover 27 years ago
Why Primary Care Physicians Join HMOsover 27 years ago
Is Prior Authorization of Topical Tretinoin for Acne Cost Effective?over 27 years ago
Disease Management of Congestive Heart Failureover 27 years ago
Celecoxib: A COX-2 InhibitorAdvertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5